AGTR2 and cardiac hypertrophy: In our experimental protocols, in presence of up to 4 weeks of administration of Ang II, the activation of either AT2 or Mas receptors was as effective in preventing fibrosis and myocardial hypertrophy as in case of blockade of AT1 receptors.